监管文件显示，CVC与比利时投资公司GBL本月将对意大利制药集团Recordati的出价提高至每股53欧元，截至要约收购期结束，该财团已获得该公司74.3%的股份。
CVC and Belgian investment firm GBL , which this month raised their bid for Italian pharmaceutical group Recordati to €53 a share, had secured a 74.3% stake in the firm by the end of the offer period, a regulatory filing showed on Friday.
这使该财团超过了其设定的66.7%最低接受门槛——该要约将Recordati估值约为110亿欧元——但未达到退市所需的90%水平。意大利证券交易所周五表示，投资者已向竞购财团申报出售Recordati股份，占股62.15%。这加上CVC在市场上收购的6.9%股份、GBL持有的3.3%股份，以及CVC通过行使衍生品获得的额外1.96%股份。竞标方将于11月3日至9日重新开放要约。
其投资工具表示，若未达到90%门槛，可能寻求与Recordati合并，使少数股东持有非上市公司的股份。据一位财务人士透露，Recordati持有约占其资本0.5%的库存股。
That put the consortium above the 66.7% minimum acceptance threshold they had set for the offer — which values Recordati at around €11 billion — but short of the 90% level required to delist the drugmaker The Italian Stock Exchange said on Friday investors had tendered Recordati shares to the bidding consortium for a 62.15% stake That adds to a further 6.9% stake acquired by CVC on the market, GBL's 3.3% holding and an additional 1.96% stake obtained by CVC through the exercise of derivatives The bidders will reopen the offer between November 3 and 9 Their vehicle has said that, should the 90% threshold not be reached, it could pursue a merger with Recordati, leaving minority shareholders with stock in an unlisted company Recordati owns treasury shares for around 0.5% of its capital, according to a financial source